An interventional study of Creatine and L-arginine and creatine in Coronary Artery Disease, sponsored by Boston University. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2007-10-31.
Sponsored by Boston University · Not applicable, Interventional, and Basic science
The study is a double blind 2x2 factorial study. Patients with coronary disease will be randomly be assigned to L-arginine (9 g/day), creatine 21 g/d, both, or neither dietary supplement. The function of the endothelium will be tested using ultrasound before and after each treatment. These studies will help us understand why the endothelium is abnormal in patients with coronary artery disease and how L-arginine is acting on endothelial function.
5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.
This study's enrollment of 119 is close to the median of 124 across 3,436 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Boston University is the lead sponsor of 266 studies on the registry; 37 are open to participants now.
Of its 30 completed or terminated interventional studies of FDA-regulated products, 24 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dietary Supplement: Creatine
Dietary Supplement: l-arginine
Dietary Supplement: L-arginine and creatine
Dietary Supplement: placebo, double
Creatine 21 g daily
L-arginine
l-arginine 9 g daily
placebo
Brachial artery flow-mediated dilation
Time frame: 5 days
serum arginine, creatine, creatinine, homocysteine
Time frame: 5 days
No study locations are listed for this record.
This study is completed, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston University